261 Cirrhotic Cardiomyopathy: An Overall Assessment and Role of NT-PROBNP

Bernal, Vanesa; Pascual, Isaac; Esquivias, Paula; Gil, Agustín García; Fernandez, C. de Souza; Agudo, J.; Serrano, Trinidad; Simón, Miguel Ángel

doi:10.1016/s0016-5085(09)63671-4

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since more than 80% of the patients with HCC had progressed from LC; therefore, these results strongly suggest that hepatic pathologic lesions, particularly cirrhosis, contribute to the elevation of NT-proBNP in patients with liver diseases. is hypothesis is in accordance with Galasko's explanation for increased NT-proBNP levels with age [30] and is also consistent with the results of Bernal's study where elevated levels of NT-proBNP were found to be independently related to the severity of cirrhosis [31]. Since elevated levels of NT-proBNP have been regarded as a risk factor for death, the extremely high levels of NT-proBNP in patients with LC predict poor outcomes.…”

Section: Discussionsupporting

confidence: 91%

The biomarker N-terminal pro-brain natriuretic peptide and liver diseases

Geng¹,

Li²,

Li³

et al. 2011

CIM

View full text Add to dashboard Cite

e biomarker N-terminal pro-brain natriuretic peptide and liver diseases Abstract Purpose: NT-proBNP has emerged as a powerful diagnostic and prognostic biomarker in heart disease. Studies showed that NT-proBNP is a sensitive biomarker for identifying patients with heart failure caused by hepatitis C virus (HCV) related myocarditis. e purpose of this study was to evaluate the correlation between the serum concentration of NT-proBNP and hepatitis virus infection/liver disease.Methods: 223 serum samples from blood donors (aged 19~50 years old) were collected as a control group, and 644 samples were obtained from patients infected by hepatitis viruses including 493 HBV: 364 chronic hepatitis (CH), 86 hepatocellular carcinoma (HCC) and 43 liver cirrhosis (LC) and 151 HCV (85 CH, 14 HCC, 52 LC). All samples were assayed with an Elecsys immunoassay analyzer for NT-proBNP concentration.Results: e mean concentration of NT-proBNP in the control group was 21.77 pg/ml and showed no signi cant variation with either age or gender. Both the mean value and the rate of abnormality of NT-proBNP were signi cantly higher for the HBVand HCV-infected groups in comparison with the control group. e mean NT-proBNP value (380.24 pg/ml) and abnormality rate (38.41%) in the HCV group were higher than that of the HBV group. For samples from patients with HBV/HCV-related hepatic disease/pathology, the mean NT-proBNP value (517.19 pg/ml/597.18 pg/ml) were the highest in the liver cirrhosis group.Conclusions: Hepatic pathologic lesions, particularly cirrhosis, may contribute to the elevation of NT-proBNP in subjects with HBV/HCV infection.

show abstract

Section: Discussionsupporting

confidence: 91%